A gene-modified diagnosing drug for testing Mycobacterium tuberculosis infections (MTI) has attained China's new drug certificate and production license, reported China Daily.
Anhui Zhifei Longcom Biopharmaceutical said the new product can avoid false positives for MTI when a person has received a Bacillus Calmette–Guérin (BCG) vaccine.
Pu Jiang, general manager of the company, explained that researchers use gene recombination technology to fuse and express ESAT6-CFP10 protein with the product, which can detect the pathogen by a skin test and distinguish it from BCG vaccinations.
He said countries with high incidences of tuberculosis such as the Philippines, Indonesia and Brazil have contacted the company, hoping to introduce the product to their markets.
To read more NewsPoints articles, click here.